Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores
Paul M. Ridker(Brigham and Women's Hospital), Nancy R. Cook(Brigham and Women's Hospital)
Cited by 514
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease
|New England Journal of Medicine|1996|2.4k
C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events
|Circulation|2003|2.3k